...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hepato-gastroenterology. >Efficacy of trimebutine therapy in patients with gastroesophageal reflux disease and irritable bowel syndrome.
【24h】

Efficacy of trimebutine therapy in patients with gastroesophageal reflux disease and irritable bowel syndrome.

机译：曲美布汀治疗对胃食管反流疾病和肠易激综合征的疗效。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND/AIMS: GERD (gastroesophageal reflux disease) occurs in 25-51% of IBS (irritable bowel syndrome) patients. Trimebutine has been effective in some IBS patients by modulating colonic motility. Furthermore, it increases gastric emptying rates, and controls esophageal motility. The aim of this study was to investigate the efficacy of trimebutine therapy in GERD patients with IBS. METHODOLOGY: Sixty-nine patients with GERD and IBS underwent upper gastrointestinal endoscopic, histologic and clinical evaluation prior to and 3 months post-treatment. H. pylori presence was determined by histology and CLOtest. Forty patients (Group A) were treated with omeprazole plus trimebutine for 3 months: in 32 H. pylori-positive patients (subgroup A1), a standard triple eradication regimen was introduced. Twenty-nine patients (Group B) were treated with omeprazole for 3 months: in 24 H. pylori-positive patients (subgroup B1), the same eradication therapy was employed. RESULTS: Specialized intestinal metaplasia of the gastroesophageal junction was observed in 20% and in 17.2% of the patients in Groups A and B, respectively. Eradication rates were similar in subgroups A1 (84%) and B1 (83%). In Group A there was a significant improvement in GERD (P = 0.003) and IBS symptoms (P < 0.0001) as well as esophagitis (P = 0.029), when compared with Group B. CONCLUSIONS: Trimebutine appears to be effective in patients with GERD and IBS.
机译：背景/目的：GERD（胃食管反流病）发生在25-51％的IBS（肠易激综合征）患者中。曲美布汀通过调节结肠运动在某些IBS患者中有效。此外，它可以增加胃排空率，并控制食道运动。这项研究的目的是研究曲美布汀治疗对GERD IBS患者的疗效。方法：69例GERD和IBS患者在治疗前和治疗后3个月接受了上消化道内镜，组织学和临床评估。幽门螺杆菌的存在通过组织学和CLOtest确定。 40名患者（A组）接受了奥美拉唑加曲美布汀治疗3个月：在32例幽门螺杆菌阳性患者（A1组）中，采用了标准的三重根除方案。 29例患者（B组）接受了奥美拉唑治疗3个月：在24例幽门螺杆菌阳性患者（B1亚组）中，采用了相同的根除疗法。结果：在A组和B组中，分别有20％和17.2％的患者发现了胃食管连接的特殊肠上皮化生。 A1（84％）和B1（83％）亚组的根除率相似。与B组相比，A组的GERD（P = 0.003）和IBS症状（P <0.0001）以及食道炎（P = 0.029）有显着改善。结论：曲美布汀似乎对GERD患者有效和IBS。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号